275 related articles for article (PubMed ID: 31411904)
1. Vulvovaginal atrophy in women after cancer.
Cox P; Panay N
Climacteric; 2019 Dec; 22(6):565-571. PubMed ID: 31411904
[TBL] [Abstract][Full Text] [Related]
2. Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause.
Cox P; Panay N
Climacteric; 2023 Aug; 26(4):367-372. PubMed ID: 37199295
[TBL] [Abstract][Full Text] [Related]
3. Ospemifene, vulvovaginal atrophy, and breast cancer.
Wurz GT; Soe LH; DeGregorio MW
Maturitas; 2013 Mar; 74(3):220-5. PubMed ID: 23332519
[TBL] [Abstract][Full Text] [Related]
4. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
Pérez-López FR; Phillips N; Vieira-Baptista P; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):746-752. PubMed ID: 34169794
[TBL] [Abstract][Full Text] [Related]
5. Vulvovaginal atrophy of menopause and its impact on sexual function in an Italian clinical cohort of post-menopausal women.
Nappi RE; Guida M; Marchesoni D; Cianci A; Pellegrino A; Remorgida V; Di Paolantonio T; Benedetti Panici P;
J Obstet Gynaecol; 2021 Feb; 41(2):290-297. PubMed ID: 33432869
[TBL] [Abstract][Full Text] [Related]
6. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe.
DiBonaventura M; Luo X; Moffatt M; Bushmakin AG; Kumar M; Bobula J
J Womens Health (Larchmt); 2015 Sep; 24(9):713-22. PubMed ID: 26199981
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy.
Wang J; Wang L
Pharmacol Res; 2021 Apr; 166():105509. PubMed ID: 33610719
[TBL] [Abstract][Full Text] [Related]
8. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.
Pinkerton JV; Bushmakin AG; Komm BS; Abraham L
Maturitas; 2017 Jun; 100():57-63. PubMed ID: 28539177
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of post-menopausal women with genitourinary syndrome of menopause: Implications for vulvovaginal atrophy diagnosis and treatment selection.
Castelo-Branco C; Biglia N; Nappi RE; Schwenkhagen A; Palacios S
Maturitas; 2015 Aug; 81(4):462-9. PubMed ID: 26071816
[TBL] [Abstract][Full Text] [Related]
10. Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy.
Pérez-López FR; Vieira-Baptista P; Phillips N; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):740-745. PubMed ID: 34036849
[TBL] [Abstract][Full Text] [Related]
11. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
12. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
The NAMS 2020 GSM Position Statement Editorial Panel
Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449
[TBL] [Abstract][Full Text] [Related]
13. Post-menopausal vulvovaginal atrophy - an overview of the current treatment options.
Szymański JK; Siekierski BP; Kajdy A; Jakiel G
Ginekol Pol; 2018; 89(1):40-47. PubMed ID: 29411346
[TBL] [Abstract][Full Text] [Related]
14. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study.
Nappi RE; Seracchioli R; Salvatore S; Cagnacci A; Di Paolantonio T; Busacca M;
Gynecol Endocrinol; 2019 May; 35(5):453-459. PubMed ID: 30700188
[TBL] [Abstract][Full Text] [Related]
15. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause.
Palacios S; Nappi RE; Bruyniks N; Particco M; Panay N;
Climacteric; 2018 Jun; 21(3):286-291. PubMed ID: 29553288
[TBL] [Abstract][Full Text] [Related]
16. The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study.
Nappi RE; Di Carlo C; Becorpi AM; Gambacciani M; De Seta F; Ribaldone R; Benedetto C; Paoletti AM;
J Obstet Gynaecol; 2020 May; 40(4):512-519. PubMed ID: 31496326
[TBL] [Abstract][Full Text] [Related]
17. Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy.
Constantine GD; Bruyniks N; Princic N; Huse D; Palmer L; Lenhart G; Blumentals WA; Nappi RE
Curr Med Res Opin; 2014 Jan; 30(1):143-8. PubMed ID: 24083677
[TBL] [Abstract][Full Text] [Related]
18. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
19. Vaginal Atrophy in Breast Cancer Survivors: Attitude and Approaches Among Oncologists.
Biglia N; Bounous VE; D'Alonzo M; Ottino L; Tuninetti V; Robba E; Perrone T
Clin Breast Cancer; 2017 Dec; 17(8):611-617. PubMed ID: 28655486
[TBL] [Abstract][Full Text] [Related]
20. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.
Nappi RE; Palacios S; Panay N; Particco M; Krychman ML
Climacteric; 2016 Apr; 19(2):188-97. PubMed ID: 26581580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]